Mumbai/IBNS, Feb. 23 -- Shares of Cipla Limited remained under pressure on Monday after the U.S. Food and Drug Administration classified the cGMP inspection of Pharmathen International SA's manufacturing facility in Rodopi, Greece, media reports said.

Pharmathen operates as a contract development and manufacturing organisation (CDMO) for global pharmaceutical companies and supplies complex formulations, including key products for Cipla.

It serves as Cipla's exclusive supply partner for Lanreotide injection in the United States, making the regulatory observations particularly significant for the Indian drugmaker's supply chain.

The company has also revised its margin guidance downward to 21%, marking the second reduction from its earlie...